News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Investigators Identify 12 Immune-Related lncRNAs That Could Impact Endometrial Cancer Prognosis

July 14, 2022
Hayley Virgil
Article

Several immune-related long noncoding RNA signatures—including PCAT19 and SCARNA9—may be associated with prognosis in patients with endometrial cancer, according to the new research.

Prognosis in patients with endometrial cancer may be potentially impacted by 12 immune-related long noncoding RNA signatures (IncRNAs) that could act as promising therapeutic targets and molecular biomarkers, according to findings from a study published in Journal of Oncology.

The lncRNAs, including ELN-AS1, AC103563.7, PCAT19, AF131215.5, LINC01871, AC084117.1, NRAV, SCARNA9, AL049539.1, POC1B-AS1, AC108134.4, and AC019080.5, correlated with factors such as patient age, pathologic grade, and International Federation of Gynecology and Obstetrics (FIGO) stage. In turn, these factors were significantly associated with patients survival. The model appeared to be accurate based on risk score (area under the curve [AUC], 0.709), age (AUC, 0.614), grade (AUC, 0.652), and stage (AUC, 0.709). Investigators also reported that AC103563.7, AL049539.1, ELN-AS1, NRAV, and POC1B-AS1 were associated with age, pathological grade, and FIGO stage; AC108134.4 and PCAT19 were associated with pathological grade and FIGO stage; and AF131215.5 and SCARNA9 were associated with pathological grade.

“By sorting and analyzing the transcriptome information of endometrial cancer samples from TCGA [The Cancer Genome Atlas] database, we identified 12 immune-related lncRNAs. These molecules may play important regulatory roles in the occurrence and development of endometrial cancer and represent potential therapeutic targets. However, their specific roles and mechanisms require further experimental validation,” the investigators wrote.

Investigators assessed 575 endometrial cancer samples for RNA sequencing data. Immune-related genes were pulled from TCGA database gene set enrichment analysis (GSEA). Investigators received immune-related lncRNAs that demonstrated a co-expressive relationship with immune-related genes. From there, a Cox regression analysis was conducted to establish a prognostic model. The model was then assessed against survival, independent prognostic, and clinical correlation analyses. Additionally, GSEA software was used to conduct a functional annotation of the lncRNAs that were included in the study.

A total of 332 immune-related genes were pulled from the GSEA datasets to pinpoint which lncRNAs correlated with prognosis. Of these, 137 immune-related genes and 363 immune-related lncRNAs demonstrated a co-expressive relationship with known immune-related genes.

Samples were broken up into high- and low-risk scores based on median risk score. Notably, survival was lower in the high-risk compared with the low-risk group. This was further confirmed when examining the risk curves in both respective groups, with survival time being notably shorter in the high-risk vs low-risk cohort.

When examining expression levels of the 12 immune-related lncRNAs across risk statuses, investigators reported that expression of AC103563.7, AF131215.5, AC084117.1, and AL049539.1 was more prevalent in those with high-risk disease and NRAV, ELN-AS1, PCAT19, AC108134.4, LINC01871, and SCARNA9 occurred more in the low-risk population. In the low expression group, LINC01871, AC108134.4, and POC1B-AS1 were associated with a lower overall survival rate compared with the high expression cohort. Moreover, in the low AC019080.5 expression group, overall survival was higher vs the high expression cohort (P <.05).

Reference

Wang Z, Liu J, Zhao R, et al. An immune-related long noncoding RNA signature as a Prognostic Biomarker for Human Endometrial Cancer. J Oncol. Published online December 10, 2021. doi:10.1155/2021/9972454

Related Videos
Dostarlimab plus chemotherapy produces notable benefits among patients with advanced, mismatch repair deficient endometrial cancer in the phase 3 RUBY trial.
Ritu Salani, MD, details the health-related quality of life benefits associated with dostarlimab in the treatment of advanced endometrial cancer, which includes improvements in back and pelvic pain.
Ritu Salani, MD, describes the concordance between blinded independent central review and provider-assessed outcomes with dostarlimab among patients with advanced recurrent endometrial cancer in the phase 3 RUBY trial.
Expert on endometrial cancer
Related Content

FDA Grants FTD to Tulmimetostat in Advanced ARID1A+ Endometrial Cancer

September 14th 2023

Diagnosis and Treatment of Endometrial Cancer

May 1st 2014

Endometrial Cancer Molecular Classification May Predict Radiotherapy Response

August 14th 2023

FDA Approves Dostarlimab in Advanced dMMR/MSI-H Endometrial Cancer

July 31st 2023

Selinexor Maintenance Yields Prolonged PFS Benefit in TP53wt Endometrial Cancer

July 26th 2023

QPOLE Test May Be a Suitable Alternative to DNA Sequencing in Endometrial Cancer

July 17th 2023

FDA Grants FTD to Tulmimetostat in Advanced ARID1A+ Endometrial Cancer

September 14th 2023

Diagnosis and Treatment of Endometrial Cancer

May 1st 2014

Endometrial Cancer Molecular Classification May Predict Radiotherapy Response

August 14th 2023

FDA Approves Dostarlimab in Advanced dMMR/MSI-H Endometrial Cancer

July 31st 2023

Selinexor Maintenance Yields Prolonged PFS Benefit in TP53wt Endometrial Cancer

July 26th 2023

QPOLE Test May Be a Suitable Alternative to DNA Sequencing in Endometrial Cancer

July 17th 2023

FDA Grants FTD to Tulmimetostat in Advanced ARID1A+ Endometrial Cancer

September 14th 2023

Diagnosis and Treatment of Endometrial Cancer

May 1st 2014

Endometrial Cancer Molecular Classification May Predict Radiotherapy Response

August 14th 2023

FDA Approves Dostarlimab in Advanced dMMR/MSI-H Endometrial Cancer

July 31st 2023

Selinexor Maintenance Yields Prolonged PFS Benefit in TP53wt Endometrial Cancer

July 26th 2023

QPOLE Test May Be a Suitable Alternative to DNA Sequencing in Endometrial Cancer

July 17th 2023
Related Content
Advertisement

Data from a phase 1/2 trial support the fast track designation for tulmimetostat as a treatment for patients with ARID1A-mutated advanced, recurrent or metastatic endometrial cancer.

FDA Grants FTD to Tulmimetostat in Advanced ARID1A+ Endometrial Cancer

September 14th 2023
Article

Data from a phase 1/2 trial support the fast track designation for tulmimetostat as a treatment for patients with ARID1A-mutated advanced, recurrent or metastatic endometrial cancer.


Diagnosis and Treatment of Endometrial Cancer

Diagnosis and Treatment of Endometrial Cancer

May 1st 2014
Podcast

In this interview we discuss the diagnosis and treatment of endometrial cancer, a gynecologic cancer that forms in the tissue lining the uterus.


Cutting out radiotherapy appears to be safe while improving quality of life in patients with POLE-mutated endometrial cancer.

Endometrial Cancer Molecular Classification May Predict Radiotherapy Response

August 14th 2023
Article

Cutting out radiotherapy appears to be safe while improving quality of life in patients with POLE-mutated endometrial cancer.


Findings from the phase 3 RUBY trial support the FDA’s approval of dostarlimab as a treatment for advanced or recurrent endometrial cancer that is either mismatch repair deficient or microsatellite instability–high.

FDA Approves Dostarlimab in Advanced dMMR/MSI-H Endometrial Cancer

July 31st 2023
Article

Findings from the phase 3 RUBY trial support the FDA’s approval of dostarlimab as a treatment for advanced or recurrent endometrial cancer that is either mismatch repair deficient or microsatellite instability–high.


A progression-free survival benefit was seen in those with TP53 wild-type advanced/recurrent endometrial cancer who were treated with selinexor maintenance regardless of microsatellite instability status.

Selinexor Maintenance Yields Prolonged PFS Benefit in TP53wt Endometrial Cancer

July 26th 2023
Article

A progression-free survival benefit was seen in those with TP53 wild-type advanced/recurrent endometrial cancer who were treated with selinexor maintenance regardless of microsatellite instability status.


The QPOLE assay may be a fast, low-cost alternative to other next-generation sequencing tools for POLE testing among patients with endometrial cancer.

QPOLE Test May Be a Suitable Alternative to DNA Sequencing in Endometrial Cancer

July 17th 2023
Article

The QPOLE assay may be a fast, low-cost alternative to other next-generation sequencing tools for POLE testing among patients with endometrial cancer.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.